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Abstract 
Malignant melanoma presenting as a giant cutaneous mass is rarely observed in clinical practice. A few patients with giant 
melanoma have been reported, Herein, we document our experience with a patient with giant cutaneous melanoma of the 
abdomen and review the features of previously reported individuals. 
Introduction 
The term "giant melanoma" is generally used to describe those cases of melanoma with a very large diameter independent of 
its depth  [1,2]. There is no cutoff diameter for diagnosis of giant melanoma, although some authors confine this term to those 
lesions having a diameter larger than 10 cm [1]. To the best of our knowledge, the first description of a giant cutaneous 
melanoma dates back to 1970, when Bazex et al. described a case in a child [3]. Since then, a few other cases have been 
described. Herein we report our experience with a giant cutaneous melanoma and we review the cases reported in literature. 
Case synopsis 
A 60-year-old woman was referred to our clinic because of an asymptomatic skin neoplasm on her abdomen. The lesion had 
appeared about eight months before and it had progressively increased in size. At first, she neglected the problem, but sought 
medical attention after the mass began bleeding.   
Physical examinations revealed a malodorous, brown-reddish, firm, bleeding vegetative mass with necrotic areas and purulent 
exudation. The dimension of the tumor was 18 cm x 15 cm x 6 cm (Figure 1).  Mild erythema appeared in the surrounding 
skin. No other significant skin or mucosal lesions were detected. A palpable lymph node in her right axilla was identified. 
 The tumor was excised with a 3 cm margin and, after histological examination, it was diagnosed as a high-grade malignant 
melanoma of Clark's level IV and Breslow's depth 40 mm, The histological sections showed large polygonal cells with very 
pleomorphic nuclei that contained prominent nucleoli. Disseminated deposits of brown melanin pigment were present in the 
entire section (Figures 2, 3).  
Total body positron emission tomography-computed tomography (PET-CT) scanning showed the involvement of an axillary 
lymph node, as already clinically revealed.  No other areas of increased hypermetabolic uptake were detected. Serum lactate 
dehydrogenase (LDH) level was normal. Needle aspiration of the enlarged lymph node revealed melanoma involvement.  
The patient underwent a right axillary nodal basin dissection. After histopathological analysis one lymph node out of twenty 
proved to be positive for melanoma involvement. At that time, six years ago, we did not perform any mutational investigation 
for BRAF, NRAS, or c-KIT in DNA obtained from the tumor tissue.  
According to the American Joint Committee on Cancer (AJCC) TNM staging system, the patient was classified as stage III C 
disease (pT4b,N1b,M0). The patient refused interferon therapy; adjuvant chemotherapy with dacarbazine at 800 mg/mq for 10 
cycles was performed. After 6 years there has been no evidence of local or distant metastasis.  
 
Figure 1. The giant vegetative melanoma of the left abdomen extending from the hypochondrium to mesogastrium.: The dimension of the 
tumor was 18 cm x 15 cm x 6 cm 
 
Figure 2. Histological section of the giant melanoma (H&E staining 40 x magnification) characterized by large polygonal cells with 
pleomorphic nuclei  
  
Figure 3.  Histological section representing the melanoma cells in the dermis (H&E staining 40 x):  Cells are large and have very 
pleomorphic nuclei that contain prominent nucleoli. Some deposits of brown melanin pigment are present.   
Discussion 
Giant melanoma has rarely been described in the literature because patients usually come for treatment earlier, and 
practitioners are well aware of the catastrophic consequences of neglecting such tumors [4]. A systematic literature review, 
limited to the English language, has shown only 16 patients with melanoma appearing as a giant cutaneous tumor (Table 1).  
Excluding a congenital case [5], giant cutaneous melanoma occurs in adults with a mean age of onset of 57 years (range 29–88 
years). There does not appear to be a sex prevalence; 8 cases occurring in both males and females have been described. The 
most common location is the back [5-9], followed by scalp [1,10,11], upper arm [2,12], thumb [4,14], abdomen (our patient 
and 14), and eyelid [15]. Most cases did not show any precursor lesion (de novo onset), but in two patients melanoma arose in 
a congenital melanocytic nevus [5,8] and in another two patients it developed from a previously acquired melanocytic nevus 
[12,15]. The diameter of the tumors have ranged between 4 and 25 cm and the Breslow thickness has varied from 0.45 mm to 
100 mm, with a mean thickness of 44 mm (average value obtained from 13 reported patients).  
The main morphologic feature of giant cutaneous melanoma is a vegetative tumor, although cases appearing as confluent 
purple-blue-grey macules, papules, and nodules covering most of the parietofrontotemporal scalp [10], and an abdominal 
plaque with a diameter of 18 cm that developed over 15 years have also been described [14]. The vegetative growths appear to 
be much thicker. This difference could relate to the different growth pattern of the two clinical variants, mainly horizontal for 
the plaque form and mostly vertical for vegetative lesions. The cases are described in Table 1. 
As we observed in our experience, most cases of giant cutaneous melanoma presented with clinically palpable regional 
lymphadenopathy, about 82% of cases in which the macroscopic lymph node status was reported (n = 11). Moreover, to our 
knowledge, only four published patients did not have metastatic disease (n = 13). The thickest vegetative giant melanoma 
(Breslow depth of 100 mm) even showed neither loco-regional nor distant metastases [11]. The reason for local or loco-
regional spread in some massive melanomas is unknown, although some authors suggested that it could be ascribed to intrinsic 
biological behavior of the tumor and patient's immunological response to the melanoma cells [8]. Those aspects are also likely 
to influence the growth rate of the tumor [2]. In reported cases it has taken from 3 months to 15 years to reach a massive size.  
Regarding the staging of the disease, only one case in this review could be staged as IIc [11]; the other cases are at least stage 
III because of the nodal involvement (Table 1). 
Table 1. Summary data of published reports referred to patients with primary giant cutaneous melanomas. 
Case Sex and 
Age (years) 
Precursor 
lesion 
Morphology 
of lesion 
Localization Length of 
growth 
Size (cm) Breslow 
thickness 
(mm) 
Nodal 
diffusion 
Metastatic 
disease 
Stage of 
disease 
Therapy 
Del Boz (12) F 29 Yes 
(AMN) 
VT Arm 8 months 20x15x7 70 Yes 
(histological 
evaluation) 
Yes IV Palliative 
debulking; 
Ax ND 
Grisham (7) F 45 No VT Back > 1 year 13xNA 55 Yes 
(palpable) 
NA Almost 
IIIC 
WLE; Ax ND; α-
interferon 
De Giorgi (14) F 45 No Skin Plaque Abdomen 15 years 16xNA 0,45 NA NA NA NA 
Kruijff (6) F 56 No VT Back NA 8x6 48 Yes 
(palpable) 
Yes IV WLE;  Bil Ax ND 
Kim (4) F 56 No VT Thumb 3 years 7x4x3,5 > 4 Yes 
(palpable) 
No IIIC Thumb amputation; 
Ax ND; INF-α-2a 
Our case F 60 No VT Abdomen 8 months 18x15x6 40 Yes 
(palpable) 
No IIIC WLE; Ax ND;  
Chemotherapy 
Zeebregts (13) F 74 No VT Thumb 7 months 5x7x5 NA NA Yes IV Local perfusion 
with γ-interferon, 
TNF-α and 
melphalan, surgical 
excision, Ax ND. 
Müller (10) F 84 No Confluent 
purple-blue-
grey macules, 
papules and 
nodules 
Scalp NA NA 5 No 
(ultrasound 
evaluation) 
NA NA None 
Harting (9) M 29 Yes 
(CMN) 
VT Back 1 year 22x25x7 54 Yes 
(palpable) 
Yes IV WLE; 
Chemotherapy  
Eisen (8) M 47 No VT Back 6 months 8x9 40 NA Yes IV WLE 
Pai (15) M 53 Yes 
(AMN) 
VT Eyelid 1 year 5x4,5 x4 45 Yes 
(palpable) 
No IIIC Excision with a 
margin of 8 mm 
Panajotovic (11) M 57 No VT Scalp 3 years 12x10 100 No (clinical 
and imaging 
evaluation) 
No Likely 
IIC 
WLE 
Tseng      patient B 
(2) 
M 63 No VT Arm > 1 year 23x21x6 75 Yes 
(palpable) 
Yes IV WLE; Ax ND 
Ching (1) M 70 No VT Scalp 3 months 14,5x 10,4 18 Yes 
(palpable) 
Yes IV WLE; SND 
Tseng      patient A 
(2) 
M 88 No VT Arm NA 10x8x3 31 Yes 
(palpable) 
Yes IV WLE; Ax ND 
Schneiderman (5) M 
Premature 
newborn 
Yes 
(CMN) 
VT Back Congenital 
lesion 
15x14x5 NA NA Yes IV None 
 
AMN: acquired melanocytic nevus; Ax ND: Axillary Nodal Dissection; Bil Ax ND: Bilateral Axillary Nodal Dissection; CMN: Congenital melanocytic nevus; NA: Not available; SND: selective 
neck dissection; TNF- α: Tumor necrosis factor-alpha; VT: Vegetative tumor; WLE: Wide local excision. 
Given the rarity of giant melanomas, it is difficult to draw any conclusion for the staging and management strategy. 
Consequently, there is no validated approach [2]. Nevertheless, for  patients with clinically positive node(s), such as in our 
case, the current National Comprehensive Cancer Network (NCCN) guidelines for melanoma suggest evaluating the palpable 
node through fine-needle aspiration, avoiding sentinel lymph node biopsy (SLNB). Furthermore, baseline imaging (CT, 
PET/CT, MRI) for staging purpose and evaluation of specific signs or symptoms are also recommended for those patients. On 
the other hand, serum LDH level is considered to be optional [16]. According to those guidelines, in our patient we have 
performed careful clinical examination of all superficial lymph node basins,, serum LDH level, and a total body PET-CT scan 
to investigate clinically occult nodal involvement or visceral metastasis. Subsequently, after checking the involvement in the 
clinically enlarged axillary lymph node through needle aspiration, we carried out nodal dissection, followed by histological 
examination. 
Regarding therapy of giant melanoma, several authors have supported an attempt to treat with multimodality treatment, 
including aggressive surgical resection.  Experimental treatment regimens and novel therapeutic agents may be considered, 
since giant melanomas are often associated with several negative prognostic factors (size, exophytic growth, ulceration, nodal 
disease) and a very poor prognosis [2]. In our patient, wide excision of the melanoma with 3-cm margins, complete axillary 
lymph node dissection, and adjuvant chemotherapy with dacarbazine 800mg/mq for 10 cycles were performed. At the present 
time, after a 6-year follow-up, the patient is free of disease and she represents the giant melanoma patient with the longest 
disease-free survival.  
Discussion 
Giant cutaneous malignant melanoma is rarely observed in clinical practice. It has rarely been described in the literature. The 
main morphologic feature of giant cutaneous melanoma is a vegetative tumor. Given the rarity of giant melanomas, it is 
difficult to draw any conclusions for the staging and management strategy.  Consequently, there is no validated therapeutic 
approach. Giant melanomas are often associated with a very poor prognosis. The reason for local or loco-regional spread in 
some massive melanomas without distant metastases is unknown, although some authors have suggested that it could be 
ascribed to the intrinsic biological behavior of the tumor and patient's immunological response to the melanoma cells  
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